Adherex Technologies (FENC) Expected to Announce Quarterly Earnings on Tuesday

Adherex Technologies (NASDAQ:FENC) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $13.7750 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last posted its earnings results on Saturday, March 28th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.21). The business had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.75 million. Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Adherex Technologies Price Performance

NASDAQ FENC traded up $0.13 during trading on Tuesday, reaching $6.78. 29,478 shares of the company’s stock traded hands, compared to its average volume of 152,289. The company’s 50 day simple moving average is $7.11 and its two-hundred day simple moving average is $7.65. Adherex Technologies has a 12-month low of $5.65 and a 12-month high of $9.92. The firm has a market cap of $234.19 million, a price-to-earnings ratio of -19.98 and a beta of 0.91.

Insider Buying and Selling

In related news, Director Rosty Raykov sold 10,781 shares of Adherex Technologies stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $6.47, for a total value of $69,753.07. Following the completion of the sale, the director directly owned 121,451 shares in the company, valued at $785,787.97. This trade represents a 8.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 11.76% of the stock is owned by company insiders.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC acquired a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on FENC shares. B. Riley Financial started coverage on shares of Adherex Technologies in a research report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adherex Technologies in a research report on Tuesday, April 21st. Zacks Research downgraded shares of Adherex Technologies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 25th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Adherex Technologies in a research report on Thursday, April 16th. Finally, Wall Street Zen downgraded shares of Adherex Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.80.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.